The Mitochondria‐Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age
Aging Cell · 2025
DOI: 10.1111/acel.70026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2025. Verfasst von Wayne Mitchell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Muscle, Skeletal, Aging, Oligopeptides, Epigenesis, Genetic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Aging‐related decreases in cardiac and skeletal muscle function are strongly associated with various comorbidities. Elamipretide (ELAM), a novel mitochondria‐targeted peptide, has demonstrated broad therapeutic efficacy in ameliorating disease conditions associated with mitochondrial dysfunction across both clinical and pre‐clinical models. Herein, we investigated the impact of 8‐week ELAM treatment on pre‐ and post‐measures of C57BL/6J mice frailty, skeletal muscle, and cardiac muscle function, coupled with post‐treatment assessments of biological age and affected molecular pathways. We found that health status, as measured by frailty index, cardiac strain, diastolic function, and skeletal muscle force, is significantly diminished with age, with skeletal muscle force changing in a sex‐dependent manner. Conversely, ELAM mitigated frailty accumulation and was able to partially reverse these declines, as evidenced by treatment‐induced increases in cardiac strain and muscle fatigue resistance. Despite these improvements, we did not detect statistically significant changes in gene expression or DNA methylation profiles indicative of molecular reorganization or reduced biological age in most ELAM‐treated groups. However, pathway analyses revealed that ELAM treatment showed pro‐longevity shifts in gene expression, such as upregulation of genes involved in fatty acid metabolism, mitochondrial translation, and oxidative phosphorylation, and downregulation of inflammation. Together, these results indicate that ELAM treatment is effective at mitigating signs of sarcopenia and cardiac dysfunction in an aging mouse model, but that these functional improvements occur independently of detectable changes in epigenetic and transcriptomic age. Thus, some age‐related changes in function may be uncoupled from changes in molecular biological age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Radiology, University of Washington, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Vadim N Gladyshev
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Mitchell, W., Pharaoh, G., Tyshkovskiy, A., Campbell, M., Marcinek, D. J., & Gladyshev, V. N. (2025). The Mitochondria‐Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. https://doi.org/10.1111/acel.70026
Vancouver
Mitchell W, Pharaoh G, Tyshkovskiy A, Campbell M, Marcinek DJ, Gladyshev VN. The Mitochondria‐Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. 2025. doi:10.1111/acel.70026
BibTeX
@article{Mitchell2025,
author = {Mitchell, Wayne and Pharaoh, Gavin and Tyshkovskiy, Alexander and Campbell, Matthew and Marcinek, David J and Gladyshev, Vadim N},
title = {The Mitochondria‐Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age},
journal = {Aging Cell},
year = {2025},
doi = {10.1111/acel.70026}
}
EUVIMED